United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Business Wire
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplantThis transplant builds on two successful UHeart transplants completed in 2022 and 2023 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024. This transplant represents several historic firsts for transplantation:This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424110823/en/A) Genetically modified source pig, 16 to 20 weeks old. B) The thymus is then explanted from the source genetically modified pig, and the thymic tissue is implanted under its kidney capsule. C) The thymus tissue matures under the kidney capsule for six to eight weeks. D) The UThymoKidney is
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $218.00 to $240.00. They now have a "neutral" rating on the stock.MarketBeat
- United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $375.00 to $400.00. They now have an "outperform" rating on the stock.MarketBeat
- United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $300.00 price target on the stock.MarketBeat
UTHR
Earnings
- 5/1/24 - Beat
UTHR
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 144
- 5/3/24 - Form 144
- UTHR's page on the SEC website